Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Trial of MK-7762 in Healthy Adults
NCT05824091Phase 1Completed
- Sponsor
- Gates Medical Research Institute
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing MK-7762 (TBD09) with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events at Day 36 and Clinically Significant Changes in Laboratory Parameters at Day 36. Started Feb 2023; status: completed.
02
Drugs
MK-7762
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05824091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824091.